Premium
The ketogenic diet and hyperbaric oxygen therapy work synergistically to slow tumor growth and increase survival time in mice with systemic metastatic cancer
Author(s) -
Poff Angela M,
Ari Csilla,
Goldhagen Craig,
Seyfried Thomas,
D'Agostino Dominic
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.863.2
Subject(s) - ketogenic diet , medicine , cancer , hypoxia (environmental) , glycolysis , cancer cell , tumor progression , warburg effect , metastasis , endocrinology , cancer research , oncology , metabolism , oxygen , chemistry , organic chemistry , psychiatry , epilepsy
Cancer energy metabolism is characterized by an abnormal dependence on glycolysis and fermentation for energy which can be exploited therapeutically by decreasing glucose availability to the tumor. The ketogenic diet (KD) is a high fat, low carbohydrate diet which decreases blood glucose and increases blood ketones and has been reported to slow cancer progression in laboratory and clinical settings. Tumor hypoxia is a consequence of abnormal vasculature and promotes cancer progression and further increases glycolytic‐dependency. Hyperbaric oxygen therapy (HBO 2 T) increases oxygen saturation within the tumor and can offset the cancer‐promoting effects of hypoxia. Since these therapies target overlapping metabolic defects within cancer cells, we tested the combined efficacy of KD+HBO 2 T on cancer progression and survival in a murine model of metastatic disease. KD alone significantly slowed tumor growth and increased mean survival time by 34%. Interestingly, while HBO 2 T alone did not influence outcome, combining the KD with HBO 2 T resulted in a supra‐additive effect, significantly slowing tumor growth and increasing mean survival time by 80% in mice with systemic metastatic cancer. Our results support the potential use of KD and HBO 2 T metabolic therapy as adjuvant treatments for patients with advanced metastatic disease. Grant Funding Source : Office of Naval Research